Hongri Pharmaceutical: Announcement of Resolutions of the 10th Meeting of the 9th Board of Directors
Tianjin Hongri Pharmaceutical Co., Ltd. Securities code: 300026 Securities abbreviation: Hongri Pharmaceutical Announcement number: 2026-046
Tianjin Hongri Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 10th Meeting of the 9th Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
The 10th meeting of the 9th board of directors of Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on July 28, 2026 in the company conference room, Building B01, Entrepreneurship Headquarters Base, Wuqing Development Zone, Tianjin, by on-site and communication voting. The meeting notice was sent by email or phone on July 17, 2026. The meeting should be attended by 12 directors, and 12 directors actually attended the meeting (including 4 directors who attended the meeting by on-site voting). The directors who voted on site at this meeting were: non-independent directors Mr. Wu Wenyuan, Mr. Lan Wujun, Mr. Dan Jiaping and Ms. Yang Yi. Some senior managers of the company attended the meeting. This meeting was held in compliance with the relevant laws and regulations such as the Company Law, the Articles of Association and the Rules of Procedure of the Board of Directors of the Company.
The meeting was chaired by Mr. Wu Wenyuan, chairman of the company, and the participating directors voted to adopt the following proposals:
- The "Proposal on the by-election of Mr. Shang Luqing as an independent director candidate for the ninth session of the Company's Board of Directors" was considered and approved;
In order to ensure the normal work of the company's board of directors, in accordance with the "Company Law", "Administrative Measures for Independent Directors of Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other laws and regulations and " According to the provisions of the Articles of Association of the Company, after the qualification review of the Nomination Committee of the Company's Board of Directors, the Board of Directors nominated Mr. Shang Luqing as an independent director candidate for the Company's Ninth Board of Directors (resume attached), with a term starting from the date of review and approval by the Company's third extraordinary shareholders' meeting in 2026 to the expiration date of the Ninth Board of Directors.
This proposal has been reviewed and approved at the Nomination Committee meeting of the company's board of directors.
This motion was passed with 12 votes in favor, 0 votes against, and 0 abstentions.
The above-mentioned independent director candidates still need to be submitted to the shareholders' meeting for review; the independent director candidate Mr. Shang Luqing has not yet obtained the independent director qualification certificate. He has made a written commitment to participate in the latest independent director qualification training and
Tianjin Hongri Pharmaceutical Co., Ltd. has obtained the independent director qualification certificate recognized by the Shenzhen Stock Exchange; the qualifications and independence of the independent director candidates must be reviewed and approved by the Shenzhen Stock Exchange before being submitted to the company's shareholders' meeting for review.
2. The "Proposal on Convening the Third Extraordinary Shareholders' Meeting in 2026" was reviewed and approved.
According to relevant regulations, the company's board of directors intends to serve as the convener and propose to convene the third extraordinary shareholders' meeting in 2026 on August 14, 2026. The specific content of this proposal is detailed in the "Notice on Convening the Third Extraordinary Shareholders' Meeting in 2026" disclosed on the website designated by the Supervisory Commission.
This motion was passed with 12 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Attachment: Resumes of independent director candidates for the ninth session of the Board of Directors.
Board of Directors of Tianjin Hongri Pharmaceutical Co., Ltd.
July 28, 2026
Tianjin Hongri Pharmaceutical Co., Ltd. Attachment:
Tianjin Hongri Pharmaceutical Co., Ltd.
Resumes of Independent Director Candidates for the Ninth Board of Directors
Shang Luqing, Chinese nationality, no right of residence abroad, male, born in February 1982, doctoral candidate and professor. Currently, he is the dean and doctoral supervisor of the School of Pharmacy of Nankai University, the director of the Antiviral Drug Research Center of Nankai University, the project leader of the National Key Laboratory of Medicinal Chemical Biology, and a national high-level young talent. He concurrently serves as a member of the Medicinal Chemistry Professional Committee of Tianjin Pharmaceutical Society and an editorial board member of academic journals such as Acta Pharma Sin B.
Mr. Shang Luqing does not hold shares in the company, and has no relationship with the company’s controlling shareholders, actual controllers, other shareholders holding more than 5% of the company’s voting shares, other directors and senior managers of the company; he has not been punished by the China Securities Regulatory Commission and other relevant departments or stock exchanges; he has not been punished by the China Securities Regulatory Commission and other relevant departments. The Supervisory Commission has published information on the public inquiry platform for illegal and untrustworthy information in the securities and futures markets or has been included in the list of dishonest persons subject to enforcement by the people's court; there are no Articles 3.2.3, 3.2.4, and 3.5.4 of the "Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" Article 3.5.5.